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Abstract
Mice have been employed as models of cancer for over a century, providing significant advances in our understanding of
this multifaceted family of diseases. In particular, orthotopic tumor xenograft mouse models are emerging as the preference
for cancer research due to increased clinical relevance over subcutaneous mouse models. In the current study, we
developed orthotopic pancreatic cancer xenograft models in mice by a minimally invasive method, ultrasound guided
injection (USGI) comparable to highly invasive surgical orthotopic injection (SOI) methods. This optimized method
prevented injection complications such as recoil of cells through the injection canal or leakage of cells out of the pancreas
into the peritoneal cavity. Tumor growth was monitored in vivo and quantified by ultrasound imaging weekly, tumors were
also detected by in vivo fluorescence imaging using a tumor targeted molecular probe. The mean tumor volumes for the
USGI and SOI models after 2 weeks of tumor growth were 205 mm
3 and 178 mm
3 respectively. By USGI of human
pancreatic cancer cell lines, human orthotopic pancreatic cancer xenografts were established. Based on ultrasound imaging,
the orthotopic human pancreatic cancer xenograft take rate was 100% for both human pancreatic cancer cell lines used,
MiaPaCa-2 and Su86.86, with mean tumor volumes of 28 mm
3and 30 mm
3. We demonstrated that this USGI method is
feasible, reproducible, facile, minimally invasive and improved compared to the highly-invasive SOI method for establishing
orthotopic pancreatic tumor xenograft models suitable for molecular imaging.
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Introduction
Mice have been employed as models of cancer for over a
century, providing significant advances in our understanding of
this multifaceted family of diseases. There are currently four main
areas of cancer research that use mouse models: basic biology and
physiology, experimental therapeutics, prevention, and genetics
susceptibility and risk. These models have proven to be useful in
validation of gene function, characterization of novel cancer genes
and tumor biomarkers, gaining insight into the molecular and
cellular mechanisms underlying tumor initiation and multistage
processes of tumorigenesis, and providing better clinical models in
which to test novel therapeutic strategies [1]. In particular, tumor
xenograft mouse models are commonly used in preclinical studies.
Human tumor xenograft models are created by the injection of
human tumor cells grown from culture into a mouse or by the
transplantation of a human tumor mass into a mouse. The
xenograft may be readily accepted by immunocompromised mice
such as athymic nude mice or severely compromised immunode-
ficient (SCID) mice [2]. There are several key advantages of using
human tumor xenografts: they feature the complexity of genetic
and epigenetic abnormalities that exist in the human tumor
population; can be used to aid in the development of individu-
alized molecular therapeutic approaches; and can be implanted
orthotopically to reproduce the organ environment in which the
tumor grows, so that the effect of the tumor on its microenviron-
ment can be modulated [3].
The two main types of human xenograft mouse models used for
cancer research, heterotopic and orthotopic are defined by the
location of the implanted xenograft. For heterotopic subcutaneous
models, the xenograft is implanted between the dermis and
underlying muscle and is typically located on the flank, on the back
or the footpad of the mouse. For over 30 years, the subcutaneous
xenograft model has been the most widely used preclinical mouse
model for cancer research because it is rapid, inexpensive, easily
reproducible, and has been considered sufficiently preclinical to
test anti-cancer drugs. The subcutaneous model also has the
advantages of providing visual confirmation that mice used in an
experiment have tumors prior to therapy; and providing a means
of assessing tumor response or growth over time, compared to
intracavitary models where animal survival is the sole measure of
response [4]. However, major disadvantages in the preclinical use
of subcutaneous xenograft models have become evident. It has
been consistently observed that drug regimens that are curative in
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significant effect on human disease. The primary cause of this
failure may be due to the observation that the subcutaneous
microenvironment is not relevant to that of the organ site of
primary or metastatic disease. Additionally, subcutaneous tumor
models rarely form metastases. These observations suggest that
heterotopic tumor models that do not represent appropriate sites
for human tumors are not predictive when used to test responses to
anti-cancer drugs [5].
To address the deficiencies of subcutaneous models, orthotopic
tumor xenografts are increasingly being explored for increased
clinical relevance. In this model, the tumor xenograft is either
implanted or injected into the equivalent organ from which the
cancer originated, or where metastases are found in patients.
Advantages of orthotopic models include use of the relevant site
for tumor-host interactions, the emergence of disease-relevant
metastases, the ability to study site-specific dependence of therapy,
organ-specific expression of genes and that clinical scenarios can
be replicated, e.g. surgical removal of primary tumor, or adjuvant
therapy of occult metastasis [5]. Major disadvantages are that
orthotopic tumor xenograft generation is labor intensive, techni-
cally challenging, expensive, requiring longer healing and recovery
time and that monitoring tumor volume requires relatively lower
throughput imaging methods compared to the use of calipers [5].
Nonetheless, orthotopic tumor models are emerging as the
preference for cancer research due to the increased clinical
relevance.
There is a strong need to develop improved models for the pre-
clinical investigation of pancreatic cancer. It is estimated that
43,140 people (21,370 men and 21,770 women) will be diagnosed
with cancer of the pancreas in 2010, and that 36,800 men and
women will die of this disease [6]. The prognosis is poor, with
fewer than 5% survival five years after diagnosis, and complete
remission is rare. No effective early detection methods have been
developed and progress in development of treatment and therapy
is stagnant. Gemcitabine has been the standard chemotherapy for
more than a decade. However, the benefit of single-agent
gemcitabine therapy in advanced and metastatic pancreatic
cancer is small [7]. The use of orthotopic xenograft models for
preclinical pancreatic cancer research may improve the develop-
ment of therapies and diagnostic imaging modalities against this
disease.
In this study, we investigated the feasibility of developing
orthotopic human pancreatic cancer xenograft models using
ultrasound guided injection (USGI) of tumor cells. Orthotopic
tumor xenograft mouse models for pancreatic cancer have been
well established for many years. However, these models require
the highly invasive surgical orthotopic implantation (SOI) of tumor
cells or chunks into the pancreas. This procedure can result in
significant trauma, requiring post-operative recovery time, and
can lead to adverse events such as infection, bleeding, tumor
adhesion to other organs, and other effects from the surgical stress,
e.g. wound healing.
Recent advancements have allowed for the development of
image-guided methods for orthotopic injection of cells or tissue
into internal organs, potentially eliminating the need for highly
invasive surgical procedures. In particular, minimally invasive
real-time ultrasound guided injection (USGI) of tumor cells can be
performed to create orthotopic xenograft models. USGI of tumors
cells has become an accepted method for developing orthotopic
hepatocellular carcinoma models. For example, a multi-drug
resistant model was successfully established in nude mice via
orthotopic implantation of multi-drug resistant human HCC cells
directed by ultrasonography [8]. We have successfully developed a
novel orthotopic xenograft model for lymph node metastasis,
where precise numbers of tumor cells were injected into the
axillary lymph nodes using ultrasound image guidance [9].
A syngeneic orthotopic murine pancreatic cancer mouse model
was developed by injection of murine pancreatic ductal adeno-
carcinoma cells, Pan02, into or near the pancreas of C57BL/6
mice using SonoCT ultrasound guidance [10]. The ultrasound
guided method was concluded to be favorable compared to the
subcutaneous model for the investigation of the influence of
immunotherapy on tumor growth [10]. However, tumors resulting
from this study appeared to be widely disseminated throughout the
abdominal cavity and not isolated solely to the pancreas, and it
was not clear whether this was a result of metastasis, or possibly
cells being released into the surrounding area during the
procedure.
Our current study is the first to report the orthotopic injection of
human pancreatic cancer cells directly into the pancreas of
immunocompromised mice by ultrasound-image guidance. We
have fully characterized the tumor take rates relative to the
surgical model and have confirmed by histology that the tumors
were initially isolated to the pancreas followed by subsequent
metastasis into the peritoneal cavity in later weeks. Additionally,
we have demonstrated that a targeted molecular imaging agent
can be specifically delivered through the vasculature to the
resulting tumors in the pancreas.
Materials and Methods
Ethics Statement
All procedures were in compliance with the Guide for the Care
and Use of laboratory Animal Resources (1996), National
Research Council, and approved by the Institutional Animal
Care and Use Committee, University of South Florida under the
approved protocol R3715. Immunocompromised mice are housed
in a clean facility with special conditions that include HEPA
filtered ventilated cage systems, autoclaved bedding, autoclaved
housing, autoclaved water, irradiated food and special cage
changing procedures. Mice are handled under aseptic conditions
including the wearing of gloves, gowns and shoe coverings.
Cell Culture
MiaPaca-2 cells (ATCC CRL-1420), SU86.86 cells (ATCC
CRL-1837), and the parental HCT116 cells (ATCC CCL-247)
were purchased from ATCC (Manassas, VA). The HCT116/
dOR+ colon cancer cells were genetically engineered from the
parental HCT116 cell line to highly over-express the d-opioid
receptor [11]. Expression of the dOR on the surface of HCT116
and HCT116/dOR+ cells was characterized prior to injection
using an in vitro time-resolved fluorescence binding assay [12].
HCT116/dOR+, and MiaPaCa-2 cells were cultured in DMEM/
F12 media (Invitrogen, Carlsbad, CA) supplemented with 10%
normal calf serum (Atlanta Biologicals, Lawrenceville, GA) and
1% penicillin/streptomycin solution (Sigma, St. Louis, MO). The
SU86.86 cells were cultured in RPMI media (Invitrogen)
supplemented with 10% FBS (Atlanta Biologicals). All cells were
grown at 37uC and 5% CO2.
Surgical Orthotopic Pancreatic Cancer Xenograft Mouse
Model
For comparison to the USGI technique, 5 female nu/nu mice 6-
8 weeks old (Harlan Sprague Dawley Inc., Indianapolis, IN)
underwent an established surgical method for orthotopic injection
of cells into the pancreas. For this procedure, mice were
anesthetized under isoflurane gas; the abdominal skin and muscle
Image Guided Method of Orthotopic Xenografting
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allow visualization of the pancreatic lobes; the pancreas was gently
retracted and positioned to allow for direct injection of a 20 mL
bolus of 1610
6 HCT116/dOR+ cells/PBS using a 1 cc syringe
with a 30 gauge needle; successful delivery of cells into the
pancreas was observed under magnification using a dissection
microscope; the pancreas was placed back within the abdominal
cavity; and both the muscle and skin layers closed with surgical
glue. Following recovery from surgery, mice were monitored and
weighed daily.
Ultrasound Imaging
The Visual Sonics Vevo 2100 Imaging Station was used for all
ultrasound imaging. Image acquisitions were performed using the
enhanced abdominal measurement package in the B-mode and 3-
D mode settings. Physiological status (ECG, respiration, blood
pressure, and body temperature) of the mice was closely monitored
during each image acquisition session. Mice were imaged prior to
tumor xenografting to establish baseline images and then imaged
weekly for up to 4 weeks using ultrasound to monitor development
of the orthotopic pancreatic cancer xenografts.
Fluorescence Imaging
Mice bearing orthotopic pancreatic xenografts of the HCT116/
dOR+ cells were administered 4.5 nmol/kg body weight of Dmt-
Tic-Cy5 by tail vein injection. Dmt-Tic-Cy5 is a high affinity
(3 nM Ki) peptidomimedic targeted probe conjugated to fluores-
cent dye (Cy5) that was used to determine the location of the
HCT116/dOR+ cells by in vivo and ex vivo fluorescence imaging
[12]. Following injection, mice were kept in a special dark
chamber and protected from light exposure as much as possible to
prevent photo bleaching of the dye. Alfalfa-free food and special
cage bedding were used to minimize autofluorescence.
In vivo and ex vivo fluorescence images were acquired using the
Caliper Life Sciences Xenogen IVIS 200 Series Imaging System.
The 615–665 nm excitation and 695–770 nm emission filters were
used. Acquisition times ranged from 0 s to 10 s to keep intensity
counts within the range of 15,000 to 60,000 to prevent saturation.
Prior to data analysis, instrument background subtractions were
performed. Living Image 3.2 Software was used to draw regions of
interest (ROIs) over the tumors to determine the mean
fluorescence signal (efficiency units). Efficiency units are calculated
by normalizing fluorescence emission images for variations in the
incident excitation light distribution on the stage. Autofluorescence
background was subtracted by determining the mean tumor
fluorescence signal prior to injection.
Histology of Pancreatic Xenografts
The pancreata of the mice were harvested, visually inspected,
fixed in 10% formalin buffer, processed, embedded, tri-sectioned,
H&E stained, and analyzed by a pathologist for the presence of
tumors.
Statistics
Data are represented as mean 6 s.d. and Student’s t-test was
used to determine significance.
Results
Development of the Orthotopic Human Pancreatic
Cancer Xenograft Mouse Model Using USGI
The orthotopic human pancreatic cancer mouse model was
developed using 6–8 week old female athymic nude mice. Mice
were anesthetized using 3% isoflurane gas via induction chamber
and then secured in dorsal recumbency on the ultrasound platform
with a nose cone for maintenance of anesthesia at 1.5 to 2%. The
ultrasound platform is positioned to have the pancreas side of the
body towards the mechanical needle holder. Ultrasound gel was
applied to the abdomen and the pancreas located by mechanically
adjusting the position of the ultrasound transducer, with the spleen
as a reference. A prescan image of the mouse abdominal region
was performed using the 3D mode imaging acquisition feature
prior to xenografting to establish a baseline for comparative
analysis. A 0.5 mL syringe with a 30 g needle was placed in the
mechanical syringe holder and lined up parallel to the probe and
perpendicular to the body. The syringe needle was then properly
aligned and advanced into the pancreas using the needle guide
overlay feature that allows for the visualization of the needle
alignment and injection target on the US monitor. A 20 mL bolus
of 1610
6 tumor cells suspended in PBS was injected directly into
the pancreas using the automated image-guided precision micro-
injection feature. An optimized injection technique was used, in
which the injection volume was decreased from an initial volume
of 50 mLt o2 0mL. Instead of immediately retracting the needle, a
5 second pause after the cell injection with a slow, deliberate
withdrawl of the needle allowed for complete delivery of cells into
the pancreas. The optimized technique prevented injection
Figure 1. Representative ultrasound images of USGI of tumor cells into the pancreas. A) Shows the 30 gauge needle in mouse pancreas
pre-injection. B) Shows the injection of a 20 mL bolus of tumor cells into the mouse pancreas.
doi:10.1371/journal.pone.0020330.g001
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leakage of cells out of the pancreas into the peritoneal cavity.
Figure 1 shows the real-time ultrasound acquired images of the
USGI of 1610
6 HCT116/dOR+ cells in a 20 mL bolus into the
mouse pancreas. Once an injection was completed, the anesthesia
was discontinued and the mouse was returned to the original
housing and observed until capable of purposeful movement. The
physiological status (heart rate, body temperature, ECG and
respiration rate) of the mice was tracked during the entire process
using the Vevo’s Advanced Physiological Monitoring Unit.
Following USGI xenografting, mice were monitored and weighed
daily to identify any signs of stress or trauma due to the procedure
and or tumor burden, and no significant weight loss or other
trauma was observed.
The HCT116/dOR+ model was chosen because we have
developed a highly specific molecular imaging probe (Dmt-Tic-
Cy5) for detection of cells expressing the human d-opioid receptor
and have previously used this probe for the in vivo and ex vivo
specific detection of HCT116/dOR+ cells by fluorescence
imaging [12]. Although not orthotopic, use of this line is also
relevant because colorectal cancer is known to form metastases in
the pancreas [13].
Initially mice bearing orthotopic xenografts of HCT116/dOR+
via SOI and USGI were imaged weekly by ultrasound for up to 4
Figure 2. Representative ultrasound images of orthotopic human pancreatic cancer xenografts in the mouse pancreas over time. A)
Normal mouse pancreas, B) 1 week post-USGI, C) 2 weeks post-USGI, D) 1 week post-SOI, and E) 2 weeks post-SOI.
doi:10.1371/journal.pone.0020330.g002
Figure 3. Comparison of representative images of SOI and USGI orthotopic pancreatic cancer xenografts models 2 weeks post-
injection of HCT116/dOR+ cells. The blue shaded area represents the tumor generated by performing 3D tumor volume measurements. A)
ultrasound image of USGI model, B) in vivo fluorescence image of USGI model, C) ex vivo fluorescence image of the mouse pancreas from the USGI
model, D) ultrasound image of SOI model, E) in vivo fluorescence image of SOI model, and F) ex vivo fluorescence image of the mouse pancreas from
the SOI model.
doi:10.1371/journal.pone.0020330.g003
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acquisition feature was used, in which a 3D motor translates the
Microscan array transducer across the abdomen to obtain multiple
2D slices that are assembled and rendered by the Vevo software
into a 3D data set of anatomical structures of the pancreas and
other abdominal organs. Figure 2 shows ultrasound images of
mouse pancreata bearing tumor xenografts acquired at time 0
(prior to injection of cells), 1 week and 2 weeks post- USGI and
SOI of cells. After 3 to 4 weeks, mice had extremely large tumors
with swollen distended abdomens, and at these later time-points,
some animals had metastases in various regions of the abdominal
cavity, e.g. the GI tract, liver, and lungs.
To demonstrate the feasibility of developing an orthotopic
pancreatic model by USGI that is comparable to SOI methods, 5
mice each underwent USGI or SOI of 1610
6 HCT116/dOR+
cells into the pancreata. Tumor growth was monitored and
quantified by ultrasound imaging weekly. After 2 weeks, large
pancreatic xenograft tumors were observed in all 10 mice by
ultrasound imaging (Figure 3). 3D volume measurements were
quantified by using the 3D-Mode Volume tool, in which volumes
are created by drawing contours around the tumor in every 10
slices the series of images to create a 3D tumor volume and
image. Figure 3 shows representative 3D ultrasound images of the
USGI (3A) and SOI (3D) mouse xenograft models 2 weeks after
injection of tumor cells. Mean tumor volumes (n=5) for the
USGI and SOI models were plotted over time in Figure 4 and
are recorded in Table 1. Mice were then administered 4.5 nmol/
kg Dmt-Tic-Cy5 probe via tail vein injection. In vivo fluorescence
images were acquired 24 h later, which provided maximum
contrast. The in vivo fluorescence images in Figure 3 showed
uptake of the fluorescent probe in the area of the pancreas for
both mouse models, indicating the presence of HCT116/dOR+
tumor cells. The in vivo mean fluorescence signal (n=5) was 2-fold
higher for SOI compared to the USGI model, p,0.002 (Figure 5).
Based on in vivo ultrasound and fluorescence imaging, the take
rate was 100% for both models while using HCT116/dOR+
tumor cells.
To determine if USGI can be used with human pancreatic
cancer cell lines, 5 mice underwent USGI of 2610
6 MiaPaCa-2
cells in a 20 mL bolus and another 5 mice underwent USGI of
2610
6 SU86.86 cells. After 2 weeks, all mice had orthotopic
pancreatic tumor xenografts observed by ultrasound imaging and
visual inspection (Figure 6). Mean tumor volumes (n=5) were
plotted over time for the MiaPaCa-2 and Su86.86 human
pancreatic tumors (Figure 7) and recorded in Table 1. Based on
in vivo ultrasound imaging, the orthotopic xenograft take rate was
100% while using both human pancreatic cancer cell lines,
MiaPaCa-2 and Su86.86.
Validation by Ex vivo Fluorescence Imaging and
Histology
Immediately after in vivo fluorescence imaging, the HCT116/
dOR+ tumor xeongraft bearing mice were humanely euthanized,
visually examined for the presence of tumors elsewhere in the
body, and major organs (heart, lung, kidneys, liver, spleen,
pancreas, GI tract) removed, and ex vivo fluorescence images
acquired 24 h post-administration of the targeted fluorescent
probe. The ex vivo mean fluorescence (n=5) acquired from
pancreata of both models was relatively the same (Figure 5). As
determined by ex vivo imaging, probe specific fluorescence was
Figure 4. Mean 3D tumor volume measurements (n=5) from
the USGI and SOI models of orthotopic pancreatic cancer
xenografts growth over time.
doi:10.1371/journal.pone.0020330.g004
Table 1. Mean 3D volume measurements of orthotopic
pancreatic cancer xenografts.
Xenograft
Model Week 1 Week 2
Mean (mm
3) S.D. Mean (mm
3) S.D.
USGI 56.0 32.7 205.0 120.0
SOI 68.1 27.0 177.5 145.8
SU86.86 12.9 6.6 28.9 12.1
MiaPaCa-2 11.6 6.5 28.2 5.3
doi:10.1371/journal.pone.0020330.t001
Figure 5. Mean normalized fluorescence (n=5) from in vivo and
ex vivo images for HCT116/dOR+ USGI and SOI orthotopic
pancreatic cancer xenografts 24 h post-injection of fluorescent
probe.
doi:10.1371/journal.pone.0020330.g005
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and a low level of fluorescence was observed in the kidneys
(Figure 8).
By histology, tumors were observed in 100% of pancreata that
underwent USGI or SOI using HCT116/dOR+ cells. Tumors
were observed in only 4 out of 5 (80%) of pancreata injected with
MiaPaCa-2 or SU86.86 cells, even though the take rate was 100%
based on the US imaging. Histology from these pancreata was
only prepared from 3 sections that were 50 mm apart, hence, it is
probable that tumors were missed during sectioning. Figure 9
shows representative H&E staining of mouse pancreata containing
tumor xenografts of all three cell lines. For HCT116/dOR+ cell
xenografts, the mean percentage (n=5) of malignant tissue relative
to unaffected tissue found in a single section of the pancreas was
76615 % for the SOI method and 62613 % for USGI (Table 2).
Each xenograft was histologically graded for type of malig-
nancy and mean percentage scored (n=5) for SOI and USGI
respectively: 84%69 and 85%69 cellular, 12%65 and 11%66
stromal, and 4%64 and 4%63 necrotic (Table 2).
Discussion
To the best of our knowledge, this is the first account of
orthotopic xenografting of human pancreatic cancer cells by USGI
into the mouse pancreas. In this study, we demonstrated that this
USGI method is feasible, reproducible, facile, minimally invasive
and improved compared to the highly-invasive SOI method for
establishing orthotopic pancreatic models suitable for molecular
imaging applications. USGI is an improvement over the SOI
method for imaging because the invasive portion of the procedure
takes only 30 seconds versus 5 minutes and with a shorter recovery
and healing time. The surgical wound was still present at the time
of fluorescence imaging 2 weeks later with the SOI method, while
the USGI needle prick wound was no longer visible after 1 day.
The presence of the surgical wound altered the autofluorescence
properties of the skin and can thus decrease the quality
fluorescence imaging studies.
Ultrasound imaging was used to track the injection of tumor
cells in vivo. The real-time visualization of the cell injections
Figure 6. Representative ultrasound acquired images of orthotopic human pancreatic cancer xenografts 2 weeks after USGI of: A)
MiaPaCa-2 cells B) SU86.86 cells. The blue shaded area represents the tumor generated by performing 3D tumor volume measurements.
doi:10.1371/journal.pone.0020330.g006
Figure 7. Mean 3D tumor volume measurements (n=5) from
the orthotopic human pancreatic cancer xenografts using
pancreatic cancer cell lines, MiaPaca-2 and SU86.86, growth
over time.
doi:10.1371/journal.pone.0020330.g007
Figure 8. Mean ex vivo fluorescence signal from mouse organs
(pancreas, spleen, heart, lungs, liver, kidneys, and GI tract)
obtained 24 h post-administration of tumor targeted fluores-
cent-probe and 2 weeks post SOI or USGI, n=5.
doi:10.1371/journal.pone.0020330.g008
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experiments, we observed cells spilling out of out the pancreas
into the peritoneal cavity when a 50 mL bolus of tumor cells was
injected directly into the pancreas by both the USGI and SOI
method. This volume was chosen initially because it was the
volume used in the syngeneic orthotopic pancreatic model
developed by Schneider et al, in which they observed abdominal
metastases in most cases [10]. We also observed abdominal
metastases in mice receiving a 50 mL bolus and suspect that these
metastases may be due to cell spillage. We also observed recoil of
cells through the injection canal when the needle was removed
from the pancreas too quickly, which resulted in 3 mice developing
a small subcutaneous tumor at the injection site. Therefore, we
optimized the injection volume to 20 mL and the injection method
to prevent spillage and recoil of cells out of the pancreas.
Initial experiments determined that orthotopic pancreatic
xenografts of HCT116/dOR+ cells exhibit peritoneal dissemina-
tion after 3 to 4 weeks, which has been reported by others as well
[14,15,16]. In this time frame, we observed metastases to the
peritoneum, liver, and lungs. Metastases were not detected at 2
weeks. Others have observed significant metastasis to the
peritoneum, liver, lungs, and lymph nodes following surgical
orthotopic injection of tumor cells into the pancreas [17]. This
suggests that pancreatic cancer xenografts using HCT116/dOR+
cells are similar to pancreatic cancer cell xenografts. Since we were
investigating the feasibility of USGI by determining tumor
xenograft take rate and not metastasis, we chose to carry out the
rest of the study using mice with 2 week-old orthotopic pancreatic
cancer xenografts.
Ultrasound and fluorescence imaging were used to identify the
location of tumors and to monitor the progress of tumor growth in
vivo. Although HCT116/dOR+ cells are human colorectal cancer
cells, they are relevant for pancreatic xenograft models because
they are known to form occult metastases in the pancreas [13].
Furthermore, they could be tracked by a molecular imaging probe
we had previously developed, the peptidomimetic fluorescent
probe (Dmt-Tic-Cy5) that specifically targets the d-opioid receptor
expressed on the surface of this tumor cell line with sub nM affinity
[12].
The success in generation of orthotopic pancreatic xenograft
tumors using USGI was comparable to our SOI methods using
HCT116/dOR+ cells. Based on ultrasound imaging, in vivo and ex
vivo fluorescence imaging, and histological analysis, the xenograft
take rate was 100% for both USGI and SOI using HCT116/
Figure 9. Representative H&E staining of mouse pancreata containing xenografts of the following cell lines: A) HCT116/dOR+,B )
MiaPaca-2 and C) SU86.86. The 20X magnification view shows normal pancreas (indicated by black arrows) adjacent to tumor cells (indicated by
red arrows).
doi:10.1371/journal.pone.0020330.g009
Table 2. Pathological grading of malignancy in 10 orthotopic pancreatic cancer xenografts established with HCT116/dOR+ cells.
Mouse Tumor Cell Normal Malignancy Malignancy Type (%)
Injection Method (%) (%) Cellular Stroma Necrosis
1 SOI 20 80 90 8 2
2 SOI 15 85 80 15 5
3 SOI 20 80 90 7 3
4 SOI 15 85 70 20 10
5 SOI 50 50 90 8 2
6 USGI 40 60 95 5 0
7U S G I 3 07 0 8 51 0 5
8 USGI 30 70 90 8 2
9 USGI 60 40 70 20 10
10 USGI 30 70 85 10 5
doi:10.1371/journal.pone.0020330.t002
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observed tumor formation using both ultrasound and fluorescence
imaging. Snyder et al., have also reported that fluorescence and
ultrasound imaging modalities are complementary approaches for
monitoring tumor progression and treatment response in preclin-
ical studies using orthotopic mouse models of human pancreatic
cancer [18]. The tumor xenograft volumes for SOI and USGI
were comparable at both 1 and 2 weeks post-implantation.
However, the quantified mean fluorescence signal (n=5) acquired
from in vivo imaging of the SOI model was 2 fold higher in
enhancement compared to the USGI model while there was no
significant difference in the quantified ex vivo signals. The increased
in vivo fluorescence signal generated from the SOI models relative
to ex vivo signal may be due to surgical complications, such as
trauma of the tissue in this region causing wound healing. The
wound at the surgical injection site was still present at the time of
fluorescence imaging, which may have increased fluorescent
properties compared to unaffected tissue. Regardless, in vivo
fluorescence imaging of the USGI model was superior to SOI, as
the quantified in vivo signal was equivalent to the ex vivo signal
obtained from the pancreas. At the 24 hr time-point post injection
of targeted fluorescent probe, a low level of fluorescence was
observed in the kidneys, spleen, heart and lungs. However the SOI
model had significantly greater signal, p,0.002, in these tissues
compared to USGI. This is possibly due to increased metastasis
from xenografts generated by SOI relative to USGI at the same
time-point post injection of cells (2 weeks). Based on the average
amount of malignancy relative to normal pancreas tissue as
determined by the pathologist (Table 1), the 2 methods yielded
nearly equal types of malignancy; with an average of 85% cellular,
11% stromal and 4% necrotic components. Hence, we have
demonstrated that orthotopic pancreatic tumor xenografting by
USGI is feasible and comparable to results obtained by SOI.
Since the initial phases of the study used colorectal cancer cells,
two human pancreatic cell lines, MiaPaCa-2 and Su86.86, were
chosen to demonstrate the feasibility of developing orthotopic
human pancreatic tumor xenografts by USGI. These cell lines
have previously been used for establishing surgical orthotopic
models of pancreatic cancer [19,20,21]. Based on the ultrasound
images acquired after 2 weeks, the tumor xenograft take rate was
100% and the measured volumes were similar. Our take rate is at
the high-end of rates reported in the literature, e.g. Ding et al.
reported that the rate of tumor establishment in the pancreas can
be anywhere from 50 to 100% using orthotopic transplantation
[22]. However, it is possible that in the negative pancreata tumors
were present in other sections not histologically examined.
Confirmation of tumor xenografts by fluorescence imaging
could not be performed because there are currently no fluorescent
probes available that specifically target these cells. However,
Hausner and colleagues have demonstrated targeted in vivo
imaging of subcutaneous pancreatic tumor xenografts by positron
emission tomography (PET) using the avb6-specific [
18F]FBA-
PEG28-A20FMDV2 peptide agent [23]. The specificity of this
PET agent could be explored in an orthotopic pancreatic cancer
model by USGI of avb6-expressing BxPC-3 cells and the non-
expressing MiaPaca-2 cells [23].
In conclusion, the USGI orthotopic human pancreatic cancer
xenograft model is both plausible and comparable to the
traditional but more invasive SOI model in developing orthotopic
models of pancreatic cancer. We have developed and optimized a
minimally invasive, rapid and reproducible method for the
generation of orthotopic human pancreatic cancer xenograft
mouse models by ultrasound-guided injection (USGI) of tumor
cells directly into the pancreas for use in molecular imaging of
cancer research.
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